These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 7522510)

  • 41. Interferon-alpha 2a does not improve response or survival when combined with dacarbazine in metastatic malignant melanoma: results of a multi-institutional Australian randomized trial.
    Thomson DB; Adena M; McLeod GR; Hersey P; Gill PG; Coates AS; Olver IN; Kefford RF; Lowenthal RM; Beadle GF
    Melanoma Res; 1993 Apr; 3(2):133-8. PubMed ID: 8518552
    [TBL] [Abstract][Full Text] [Related]  

  • 42. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
    Rudolf Z; Strojan P
    Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Spermidine level as a parameter in the treatment of patients with malignant melanoma.
    Smit JM; Jurjens H; Bouman J; Bijzet J; Sleijfer DT; Woldring MG; Mulder NH
    Eur J Nucl Med; 1985; 10(5-6):276-7. PubMed ID: 2580707
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma.
    Falkson CI; Falkson G; Falkson HC
    J Clin Oncol; 1991 Aug; 9(8):1403-8. PubMed ID: 2072144
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Actinomycin-D plus 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamine (DTIC) with or without intravenous Corynebacterium parvum in metastatic malignant melanoma.
    Robidoux A; Gutterman JU; Bodey GP; Hersh EM
    Cancer; 1982 Jun; 49(11):2246-51. PubMed ID: 7042068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Single-dose dacarbazine and dactinomycin in advanced malignant melanoma.
    Hochster H; Levin M; Speyer J; Dunleavy S; Harris M; Roses D; Golomb F; Muggia F
    Cancer Treat Rep; 1985 Jan; 69(1):39-42. PubMed ID: 3967259
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase II study of interferon alpha-2a and dacarbazine in advanced melanoma.
    Bajetta E; Negretti E; Giannotti B; Brogelli L; Brunetti I; Sertoli MR; Bernengo MG; Sofra MC; Maifredi G; Zumiani G
    Am J Clin Oncol; 1990 Oct; 13(5):405-9. PubMed ID: 2220660
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD) plus interferon alpha for metastatic melanoma: a multicentre phase II study.
    Punt CJ; van Herpen CM; Jansen RL; Vreugdenhil G; Muller EW; de Mulder PH
    Br J Cancer; 1997; 76(2):266-9. PubMed ID: 9231931
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Current results with surgery and adjuvant chemotherapy in malignant melanoma].
    Mechl Z; Kopecný J
    Arch Geschwulstforsch; 1986; 56(5):367-71. PubMed ID: 2429631
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
    Legha SS
    Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase II study of biochemotherapy for the treatment of metastatic malignant melanoma.
    Gibbs P; Iannucci A; Becker M; Allen J; O'Driscoll M; McDowell K; Williams P; Rosse P; Murphy J; Gonzalez R
    Melanoma Res; 2000 Apr; 10(2):171-9. PubMed ID: 10803718
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database.
    Khan MA; Andrews S; Ismail-Khan R; Munster PN; Brem S; King J; Reintgen DS; Sondak VK; Daud AI
    Cancer Control; 2006 Jul; 13(3):211-7. PubMed ID: 16885917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma.
    Pyrhönen S; Hahka-Kemppinen M; Muhonen T
    J Clin Oncol; 1992 Dec; 10(12):1919-26. PubMed ID: 1280673
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study.
    Falkson CI; Ibrahim J; Kirkwood JM; Coates AS; Atkins MB; Blum RH
    J Clin Oncol; 1998 May; 16(5):1743-51. PubMed ID: 9586887
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
    Garbe C
    Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Updated analysis of an outpatient chemoimmunotherapy regimen for treating metastatic melanoma.
    Thompson JA; Gold PJ; Markowitz DR; Byrd DR; Lindgren CG; Fefer A
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S29-34. PubMed ID: 9457390
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Similar efficacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011.
    Luke JJ; Rubinstein LV; Smith GL; Ivy SP; Harris PJ
    Melanoma Res; 2013 Apr; 23(2):152-8. PubMed ID: 23411478
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sequential administration of varying doses of dacarbazine and fotemustine in advanced malignant melanoma.
    Lee SM; Margison GP; Woodcock AA; Thatcher N
    Br J Cancer; 1993 Jun; 67(6):1356-60. PubMed ID: 8512821
    [TBL] [Abstract][Full Text] [Related]  

  • 59. BOLD+interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy.
    Nathan FE; Berd D; Sato T; Shield JA; Shields CL; De Potter P; Mastrangelo MJ
    J Exp Clin Cancer Res; 1997 Jun; 16(2):201-8. PubMed ID: 9261748
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hodgkin's disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony- stimulating factor.
    Gastaldi R; Martino P; Gentile G; Picardi V; De Propris MS; Pirillo MF; De Vellis A; Mandelli F
    Ann Oncol; 2002 Jul; 13(7):1158-60. PubMed ID: 12176798
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.